




Ophthotech Corp.  
Investor Relations Department  
Five Vaughn Drive  
Suite 106  
Princeton, NJ 08540  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#) 

#### NASDAQ: OPHT <sup>1</sup>

Last Trade:	2.71
Trade Time:	3:43 PM ET Sep 21, 2017
Change:	-0.08  (2.867%)
Day Range	2.65 - 2.80
52-Week Range	2.24 - 59.46
Volume	641,193
Market Cap. (\$M)	97.397
Shares Out (M)	35.940


<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

... [\(more\)](#)

## Stock Performance



## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Second Quarter Financial Results](#)

*Feb 28, 2017*

[Annual Report \(10-K\)](#)

*Apr 24, 2017*

[Definitive Proxy Statement](#)

*Aug 2, 2017*

[Quarterly Report \(10-Q\)](#)

*May 3, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)